JPH09507499A - ５−ニトロイミダゾール誘導体の微粒剤 - Google Patents
５−ニトロイミダゾール誘導体の微粒剤Info
- Publication number
- JPH09507499A JPH09507499A JP7518878A JP51887895A JPH09507499A JP H09507499 A JPH09507499 A JP H09507499A JP 7518878 A JP7518878 A JP 7518878A JP 51887895 A JP51887895 A JP 51887895A JP H09507499 A JPH09507499 A JP H09507499A
- Authority
- JP
- Japan
- Prior art keywords
- microgranules
- form according
- galenical form
- sustained release
- sustained
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000004958 5-nitroimidazoles Chemical class 0.000 title claims abstract description 22
- 239000008187 granular material Substances 0.000 title claims abstract description 18
- 238000013268 sustained release Methods 0.000 claims abstract description 29
- 239000012730 sustained-release form Substances 0.000 claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 27
- 230000002496 gastric effect Effects 0.000 claims description 20
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical group CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 12
- 230000007935 neutral effect Effects 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 11
- 238000000576 coating method Methods 0.000 claims description 11
- 229960000282 metronidazole Drugs 0.000 claims description 10
- 239000000454 talc Substances 0.000 claims description 9
- 229910052623 talc Inorganic materials 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 7
- 239000011230 binding agent Substances 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 6
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- KPQZUUQMTUIKBP-UHFFFAOYSA-N 1-(2-methyl-5-nitro-1-imidazolyl)-2-propanol Chemical compound CC(O)CN1C(C)=NC=C1[N+]([O-])=O KPQZUUQMTUIKBP-UHFFFAOYSA-N 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 230000001419 dependent effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 4
- 239000002245 particle Substances 0.000 claims description 4
- 239000004014 plasticizer Substances 0.000 claims description 4
- 229960004076 secnidazole Drugs 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000002178 gastroprotective effect Effects 0.000 claims description 3
- 239000007903 gelatin capsule Substances 0.000 claims description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 3
- 230000024241 parasitism Effects 0.000 claims description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 3
- 241000589989 Helicobacter Species 0.000 claims description 2
- HJLSLZFTEKNLFI-UHFFFAOYSA-N Tinidazole Chemical compound CCS(=O)(=O)CCN1C(C)=NC=C1[N+]([O-])=O HJLSLZFTEKNLFI-UHFFFAOYSA-N 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims description 2
- 229940127555 combination product Drugs 0.000 claims description 2
- 229960005053 tinidazole Drugs 0.000 claims description 2
- 229920002845 Poly(methacrylic acid) Polymers 0.000 claims 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 125000005396 acrylic acid ester group Chemical group 0.000 claims 1
- 239000004503 fine granule Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 210000001035 gastrointestinal tract Anatomy 0.000 description 9
- 208000030852 Parasitic disease Diseases 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 208000004881 Amebiasis Diseases 0.000 description 6
- 206010001980 Amoebiasis Diseases 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 5
- 208000031513 cyst Diseases 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000007664 blowing Methods 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 208000000718 duodenal ulcer Diseases 0.000 description 2
- 229940063190 flagyl Drugs 0.000 description 2
- -1 hydroxypropoxy groups Chemical group 0.000 description 2
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000025371 Taste disease Diseases 0.000 description 1
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical class O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019656 metallic taste Nutrition 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9400394A FR2715067B1 (fr) | 1994-01-14 | 1994-01-14 | Nouvelle forme galénique de dérivés de 5-nitro-imidazole efficace pour le traitement des parasitoses et des infections de l'ensemble du tractus gastro-intestinal. |
| FR94/00394 | 1994-01-14 | ||
| PCT/FR1995/000039 WO1995019168A1 (fr) | 1994-01-14 | 1995-01-12 | Microgranules de derives de 5-nitro imidazole |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH09507499A true JPH09507499A (ja) | 1997-07-29 |
Family
ID=9459066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP7518878A Pending JPH09507499A (ja) | 1994-01-14 | 1995-01-12 | ５−ニトロイミダゾール誘導体の微粒剤 |
Country Status (19)
| Country | Link |
|---|---|
| JP (1) | JPH09507499A (cs) |
| KR (1) | KR100320140B1 (cs) |
| CN (1) | CN1088357C (cs) |
| AT (1) | ATE187068T1 (cs) |
| AU (1) | AU705570B2 (cs) |
| BR (1) | BR9506507A (cs) |
| CZ (1) | CZ286080B6 (cs) |
| DE (1) | DE69513632T2 (cs) |
| DK (1) | DK0739201T3 (cs) |
| ES (1) | ES2139883T3 (cs) |
| MA (1) | MA23429A1 (cs) |
| MX (1) | MX9602772A (cs) |
| NZ (1) | NZ279238A (cs) |
| OA (1) | OA10583A (cs) |
| PL (1) | PL178424B1 (cs) |
| PT (1) | PT739201E (cs) |
| RU (1) | RU2152212C1 (cs) |
| SK (1) | SK282066B6 (cs) |
| UA (1) | UA28031C2 (cs) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003192579A (ja) * | 2001-10-17 | 2003-07-09 | Takeda Chem Ind Ltd | 酸に不安定な薬物の高含量顆粒 |
| JP2017526697A (ja) * | 2014-09-05 | 2017-09-14 | シンビオミックス セラピューティクス、エルエルシー | 細菌性膣炎の治療に使用するためのセクニダゾール |
| US12280037B2 (en) | 2020-09-22 | 2025-04-22 | Evofem Biosciences, Inc. | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2220711C1 (ru) * | 2002-04-24 | 2004-01-10 | Закрытое акционерное общество "Брынцалов-А" | Противомикробное и противопротозойное средство "трихоброл" |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4346095A (en) * | 1978-02-10 | 1982-08-24 | Mercer James B | Therapeutic treatment for viral hepatitis infection |
| US5256684A (en) * | 1985-06-13 | 1993-10-26 | The Procter & Gamble Company | Methods and compositions for the treatment of gastrointestinal disorders |
| DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
| AU7909691A (en) * | 1990-05-14 | 1991-12-10 | Gary R. Jernberg | Surgical implant and method incorporating chemotherapeutic agents |
| FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
-
1995
- 1995-01-12 DK DK95907683T patent/DK0739201T3/da active
- 1995-01-12 SK SK914-96A patent/SK282066B6/sk unknown
- 1995-01-12 PL PL95315530A patent/PL178424B1/pl not_active IP Right Cessation
- 1995-01-12 NZ NZ279238A patent/NZ279238A/en unknown
- 1995-01-12 ES ES95907683T patent/ES2139883T3/es not_active Expired - Lifetime
- 1995-01-12 MX MX9602772A patent/MX9602772A/es not_active IP Right Cessation
- 1995-01-12 RU RU96117257/14A patent/RU2152212C1/ru not_active IP Right Cessation
- 1995-01-12 DE DE69513632T patent/DE69513632T2/de not_active Expired - Fee Related
- 1995-01-12 CN CN95191222A patent/CN1088357C/zh not_active Expired - Fee Related
- 1995-01-12 AU AU15803/95A patent/AU705570B2/en not_active Ceased
- 1995-01-12 PT PT95907683T patent/PT739201E/pt unknown
- 1995-01-12 BR BR9506507A patent/BR9506507A/pt not_active IP Right Cessation
- 1995-01-12 KR KR1019960703797A patent/KR100320140B1/ko not_active Expired - Fee Related
- 1995-01-12 AT AT95907683T patent/ATE187068T1/de not_active IP Right Cessation
- 1995-01-12 JP JP7518878A patent/JPH09507499A/ja active Pending
- 1995-01-12 CZ CZ19962055A patent/CZ286080B6/cs not_active IP Right Cessation
- 1995-01-12 UA UA96083232A patent/UA28031C2/uk unknown
- 1995-01-13 MA MA23756A patent/MA23429A1/fr unknown
-
1996
- 1996-07-12 OA OA60863A patent/OA10583A/fr unknown
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003192579A (ja) * | 2001-10-17 | 2003-07-09 | Takeda Chem Ind Ltd | 酸に不安定な薬物の高含量顆粒 |
| JP2017526697A (ja) * | 2014-09-05 | 2017-09-14 | シンビオミックス セラピューティクス、エルエルシー | 細菌性膣炎の治療に使用するためのセクニダゾール |
| US10849884B2 (en) | 2014-09-05 | 2020-12-01 | Lupin Inc. | Secnidazole for use in the treatment of bacterial vaginosis |
| US10857133B2 (en) | 2014-09-05 | 2020-12-08 | Lupin Inc. | Secnidazole for use in the treatment of bacterial vaginosis |
| JP2021042246A (ja) * | 2014-09-05 | 2021-03-18 | ルピン・インコーポレイテッド | 細菌性膣炎の治療に使用するためのセクニダゾール |
| US11000508B2 (en) | 2014-09-05 | 2021-05-11 | Lupin Inc. | Secnidazole for use in the treatment of trichomoniasis |
| US11000507B2 (en) | 2014-09-05 | 2021-05-11 | Lupin Inc. | Secnidazole for use in the treatment of bacterial vaginosis |
| US11020377B2 (en) | 2014-09-05 | 2021-06-01 | Lupin Inc. | Secnidazole for use in the treatment of bacterial vaginosis |
| US11324721B2 (en) | 2014-09-05 | 2022-05-10 | Lupin Inc. | Secnidazole for use in the treatment of trichomoniasis |
| US11602522B2 (en) | 2014-09-05 | 2023-03-14 | Lupin Inc. | Secnidazole for use in the treatment of sexually transmitted infection |
| US11684607B2 (en) | 2014-09-05 | 2023-06-27 | Lupin, Inc. | Secnidazole for use in the treatment of bacterial vaginosis |
| US12280037B2 (en) | 2020-09-22 | 2025-04-22 | Evofem Biosciences, Inc. | Method and pharmaceutical composition for treating or preventing trichomoniasis and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| SK282066B6 (sk) | 2001-10-08 |
| DK0739201T3 (da) | 2000-05-01 |
| MX9602772A (es) | 1997-05-31 |
| BR9506507A (pt) | 1997-09-09 |
| KR100320140B1 (ko) | 2002-07-02 |
| AU1580395A (en) | 1995-08-01 |
| RU2152212C1 (ru) | 2000-07-10 |
| UA28031C2 (uk) | 2000-10-16 |
| CZ286080B6 (cs) | 2000-01-12 |
| PT739201E (pt) | 2000-05-31 |
| CN1088357C (zh) | 2002-07-31 |
| CZ205596A3 (en) | 1996-10-16 |
| OA10583A (en) | 2002-07-10 |
| MA23429A1 (fr) | 1995-10-01 |
| PL315530A1 (en) | 1996-11-12 |
| SK91496A3 (en) | 1996-12-04 |
| AU705570B2 (en) | 1999-05-27 |
| ATE187068T1 (de) | 1999-12-15 |
| NZ279238A (en) | 1998-03-25 |
| DE69513632T2 (de) | 2000-04-06 |
| DE69513632D1 (de) | 2000-01-05 |
| PL178424B1 (pl) | 2000-04-28 |
| CN1138826A (zh) | 1996-12-25 |
| ES2139883T3 (es) | 2000-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6551620B2 (en) | Pellet formulation for the treatment of the intestinal tract | |
| US20070128276A1 (en) | Controlled release compositions comprising nimesulide | |
| US20110064808A1 (en) | Extended release formulation of levetiracetam | |
| TWI483748B (zh) | 含有氫嗎啡酮（ｈｙｄｒｏｍｏｒｐｈｏｎｅ）和納洛酮（ｎａｌｏｘｏｎｅ）之藥學組成物 | |
| JP2000514830A (ja) | 急速に放出し且つ味を隠蔽する医薬剤形 | |
| CA3077514C (en) | Delayed release deferiprone tablets and methods of using the same | |
| WO2008062446A2 (en) | An extended release composition of levetiracetam, which exhibits no adverse food effect | |
| JP2001512433A (ja) | シスプラチン含有マイクロ顆粒 | |
| JP2001106632A (ja) | 緩下剤の効力を高める方法及び組成物 | |
| CN109893516A (zh) | 用于治疗幽门螺杆菌的药物组合物 | |
| WO2004052345A1 (en) | Coating composition for taste masking coating and methods for their application and use | |
| JP2001519782A (ja) | 新規製剤 | |
| WO2005058282A1 (en) | Double pellet formulation of proton pump inhibitors and clarithromycin for the treatment of gastrointestinal ulcer, and method for producing the same | |
| US20070154550A1 (en) | Pharmaceutical composition comprising anticonvulsant with taste mask coating | |
| JPS63258809A (ja) | 医薬活性成分の放出性にすぐれ、かつ苦味を隠蔽した細粒剤 | |
| JP2004512298A (ja) | 遅延及び持続放出製剤、及びそれを使用する方法 | |
| KR102568681B1 (ko) | 네포팜을 포함하는 경구 붕해 약학 조성물 및 그 제조 방법 | |
| US5549911A (en) | Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract | |
| JPH09507499A (ja) | ５−ニトロイミダゾール誘導体の微粒剤 | |
| EP1539113A2 (en) | Modified release ketoprofen dosage form | |
| JP2004035535A (ja) | 非ステロイド系抗炎症薬剤を含む経口医薬組成物及びその製造方法 | |
| EP0739201B1 (fr) | Microgranules de derives de 5-nitro imidazole | |
| JP2002518330A (ja) | 処置方法 | |
| CN1524517B (zh) | 含非甾体消炎药的口服药物组合物及其制备方法 | |
| KR20240101859A (ko) | 플라복세이트의 제어-방출 제형 및 이의 제조 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040323 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040623 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040809 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040924 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20050301 |